Tetraphase climbs on Phase III cIAI data
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) jumped $4.81 (14%) to $38 on Thursday after IV eravacycline met the primary endpoint in the Phase III IGNITE 1 trial to treat complicated intra-abdominal infection (cIAI). Eravacycline showed a statistically non-inferior clinical response at the test-of-cure visit 25-31 days post-treatment compared to Invanz ertapenem from Merck & Co. Inc. (NYSE:MRK). The biotech plans to submit data for presentation at a scientific meeting next year.
Tetraphase rose $1.93 (15%) to $15.01 on Sept. 3 after reporting that IV-to-oral regimens of eravacycline compared "favorably" to levofloxacin on FDA- and EMA-defined primary endpoints in the lead-in portion of the Phase III IGNITE 2 trial to treat complicated urinary tract infection (cUTI). The company said the lead-in portion was not designed to show statistical significance. Tetraphase started the pivotal portion of IGNITE 2 in October and expects topline data in mid-2015. ...